$KRYS
Krystal Biotech, Inc. Stock $krys

$krys Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000171127923000008 Filed on February 27, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$24.04M	$24.03M	$77.74M
YoY Change	51.09%	86.76%	92.46%
% of Gross Profit
Research & Development	$12.29M	$10.74M	$42.46M
YoY Change	31.93%	19.23%	52.28%
% of Gross Profit
Depreciation & Amortization	$1.100M	$1.089M	$4.055M
YoY Change	138.1%	38.9%	46.44%
% of Gross Profit
Operating Expenses	$48.82M	$34.77M	$145.2M
YoY Change	-2.79%	58.95%	112.66%
Operating Profit	-$48.82M		-$145.2M
YoY Change	-2.79%		112.66%
Interest Expense	$3.526M	$2.719M	$0.00
YoY Change		3784.29%	-100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$45.30M	-$32.05M	-$140.0M
YoY Change	-9.34%	46.99%	101.2%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$45.30M	-$32.05M	-$140.0M
YoY Change	-9.34%	46.99%	101.2%
Net Earnings / Revenue
Basic Earnings Per Share	-$1.76		-$5.49
Diluted Earnings Per Share	-$1.76	-$1.25	-$5.49
COMMON SHARES
Basic Shares Outstanding	25.76M shares	25.75M shares	25.49M shares
Diluted Shares Outstanding	25.71M shares		25.49M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$350.4M	$379.2M	$379.2M
YoY Change	-19.38%	-13.45%	-13.45%
Cash & Equivalents	$140.7M	$161.9M	$161.9M
Short-Term Investments	$209.6M	$217.3M	$217.3M
Other Short-Term Assets	$5.042M	$4.608M	$4.608M
YoY Change	49.79%	10.48%	10.48%
Inventory		$0.00
Prepaid Expenses
Receivables		$0.00
Other Receivables
Total Short-Term Assets	$355.4M	$383.8M	$383.8M
YoY Change	-18.85%	-13.22%	-13.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$163.1M	$161.7M	$169.7M
YoY Change	19.09%	43.9%	41.93%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$5.129M	$4.621M	$4.621M
YoY Change	-84.62%	-92.82%	-92.82%
Other Assets	$402.0K	$324.0K	$324.0K
YoY Change	156.05%	337.84%	337.84%
Total Long-Term Assets	$176.4M	$174.7M	$174.7M
YoY Change	-1.37%	-5.08%	-5.08%
TOTAL ASSETS
Total Short-Term Assets	$355.4M	$383.8M	$383.8M
Total Long-Term Assets	$176.4M	$174.7M	$174.7M
Total Assets	$531.8M	$558.5M	$558.5M
YoY Change	-13.78%	-10.83%	-10.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.109M	$3.981M	$3.981M
YoY Change	-49.95%	-52.6%	-52.6%
Accrued Expenses	$30.60M	$24.56M	$24.56M
YoY Change	-41.09%	43.03%	43.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$35.08M	$28.85M	$28.85M
YoY Change	-41.96%	12.09%	12.09%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.205M	$7.372M	$7.372M
YoY Change	-8.6%	5.57%	5.57%
Total Long-Term Liabilities	$7.205M	$7.372M	$7.372M
YoY Change	-8.6%	5.57%	5.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$35.08M	$28.85M	$28.85M
Total Long-Term Liabilities	$7.205M	$7.372M	$7.372M
Total Liabilities	$42.28M	$36.22M	$36.22M
YoY Change	-38.11%	10.7%	10.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$326.1M	-$280.8M
YoY Change	71.0%	99.45%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$489.6M	$522.2M	$522.2M
YoY Change
Total Liabilities & Shareholders Equity	$531.8M	$558.5M	$558.5M
YoY Change	-13.78%	-10.83%	-10.83%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$45.30M	-$32.05M	-$140.0M
YoY Change	-9.34%	46.99%	101.2%
Depreciation, Depletion And Amortization	$1.100M	$1.089M	$4.055M
YoY Change	138.1%	38.9%	46.44%
Cash From Operating Activities	-$26.16M	-$22.33M	-$100.6M
YoY Change	68.82%	6.84%	109.79%
INVESTING ACTIVITIES
Capital Expenditures	$5.381M	$5.217M	$52.98M
YoY Change	-68.7%	-112.76%	-22.47%
Acquisitions
YoY Change
Other Investing Activities	$8.944M	$9.000K	-$61.10M
YoY Change	-123.1%	-100.01%	-61.43%
Cash From Investing Activities	$3.563M	-$5.208M	-$114.1M
YoY Change	-106.37%	-95.88%	-49.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$36.00M
YoY Change			-89.88%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.474M	3.069M	$35.35M
YoY Change	-371.96%	-98.48%	-89.83%
NET CHANGE
Cash From Operating Activities	-$26.16M	-22.33M	-$100.6M
Cash From Investing Activities	$3.563M	-5.208M	-$114.1M
Cash From Financing Activities	$1.474M	3.069M	$35.35M
Net Change In Cash	-$21.16M	-24.47M	-$179.3M
YoY Change	-70.59%	-144.79%	-345.76%
FREE CASH FLOW
Cash From Operating Activities	-$26.16M	-$22.33M	-$100.6M
Capital Expenditures	$5.381M	$5.217M	$52.98M
Free Cash Flow	-$31.54M	-$27.55M	-$153.5M
YoY Change	-3.51%	-237.85%	32.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001711279
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38210
CY2022	dei	Entity Registrant Name EntityRegistrantName	Krystal Biotech, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1080209
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2100 Wharton Street
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 701
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Pittsburgh
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	15203
CY2022	dei	City Area Code CityAreaCode	412
CY2022	dei	Local Phone Number LocalPhoneNumber	586-5830
CY2022	dei	Security12b Title Security12bTitle	Common Stock
CY2022	dei	Trading Symbol TradingSymbol	KRYS
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4608000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4171000	usd
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	1400000000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25763743	shares
CY2022	dei	Auditor Name AuditorName	KPMG, LLP
CY2022	dei	Auditor Location AuditorLocation	Pittsburgh, PA
CY2022	dei	Auditor Firm AuditorFirmId	185
CY2021	dei	Auditor Name AuditorName	Mayer Hoffman McCann P.C.
CY2021	dei	Auditor Location AuditorLocation	San Diego, CA
CY2021	dei	Auditor Firm AuditorFirmId	199
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	161900000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	341246000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	217271000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	96850000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	383779000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	442267000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	161684000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	112355000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	4621000	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	64371000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8042000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7228000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	324000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	74000	usd
CY2022Q4	us-gaap	Assets Assets	558450000	usd
CY2021Q4	us-gaap	Assets Assets	626295000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3981000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8398000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1561000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1041000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	23305000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	16297000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	28847000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25736000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7372000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6983000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	36219000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	32719000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25763743	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25763743	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25207985	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25207985	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	803718000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	734523000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-728000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-163000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-280759000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-140784000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	522231000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	593576000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	558450000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	626295000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42461000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27884000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17936000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	77735000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40391000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15063000	usd
CY2022	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	25000000	usd
CY2021	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	usd
CY2020	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	145196000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	68275000	usd
CY2020	us-gaap	Operating Expenses OperatingExpenses	32999000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-145196000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-68275000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-32999000	usd
CY2022	krys	Interest Income Expense And Other Nonoperating Net InterestIncomeExpenseAndOtherNonoperatingNet	5221000	usd
CY2021	krys	Interest Income Expense And Other Nonoperating Net InterestIncomeExpenseAndOtherNonoperatingNet	197000	usd
CY2020	krys	Interest Income Expense And Other Nonoperating Net InterestIncomeExpenseAndOtherNonoperatingNet	832000	usd
CY2022	us-gaap	Interest Expense InterestExpense	0	usd
CY2021	us-gaap	Interest Expense InterestExpense	1492000	usd
CY2020	us-gaap	Interest Expense InterestExpense	0	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-69570000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32167000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-169000	usd
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-140540000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-69739000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32171000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.49
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.49
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.13
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.13
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.71
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.71
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25491721	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25491721	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22196846	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22196846	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18787161	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18787161	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	202914000	usd
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	118035000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3306000	usd
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32167000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	292084000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	355628000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15603000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-169000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-69570000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	593576000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	36063000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	649000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	33781000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-565000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-139975000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	522231000	usd
CY2022	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-78000	usd
CY2021	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	7000	usd
CY2020	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-1000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-139975000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-69570000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32167000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4055000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2769000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1851000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	33230000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	15319000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	3272000	usd
CY2022	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	-72000	usd
CY2021	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	0	usd
CY2020	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	-33000	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	0	usd
CY2021	us-gaap	Other Noncash Expense OtherNoncashExpense	1492000	usd
CY2020	us-gaap	Other Noncash Expense OtherNoncashExpense	0	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-762000	usd
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-454000	usd
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	11000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	311000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	691000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1922000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	150000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-65000	usd
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	934000	usd
CY2022	krys	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-647000	usd
CY2021	krys	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-285000	usd
CY2020	krys	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	685000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1254000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	712000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	783000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5173000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2705000	usd
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2305000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-100569000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47938000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26083000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	52979000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	68336000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14843000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	318781000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	190462000	usd
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	3205000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	257677000	usd
CY2021	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	32028000	usd
CY2020	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	6867000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-114083000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-226770000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11181000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	35996000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	355645000	usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	118019000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	649000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2022	krys	Payments For Suit Liability PaymentsForSuitLiability	0	usd
CY2021	krys	Payments For Suit Liability PaymentsForSuitLiability	7960000	usd
CY2020	krys	Payments For Suit Liability PaymentsForSuitLiability	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	35347000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	347685000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	118019000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-41000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-179346000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	72977000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	80755000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	341246000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	268269000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187514000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	161900000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	341246000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	268269000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	14927000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	15363000	usd
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9697000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1556000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4396000	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	911000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-280800000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	379200000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be </span></div>representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, including: stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company’s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.</span></div>
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-139975000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-69570000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32167000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25491721	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25491721	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22196846	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22196846	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18787161	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18787161	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.49
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.49
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.13
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.13
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.71
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.71
CY2022Q4	krys	Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost	384448000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	179000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	835000	usd
CY2022Q4	krys	Cash Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsAndDebtSecuritiesAvailableForSale	383792000	usd
CY2021Q4	krys	Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost	502636000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	11000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	180000	usd
CY2021Q4	krys	Cash Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsAndDebtSecuritiesAvailableForSale	502467000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	168477000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	116569000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6793000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4214000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	161684000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	112355000	usd
CY2022	us-gaap	Depreciation Depreciation	2600000	usd
CY2021	us-gaap	Depreciation Depreciation	1800000	usd
CY2020	us-gaap	Depreciation Depreciation	1500000	usd
CY2022Q4	krys	Accrued Preclinical And Clinical Expenses AccruedPreclinicalAndClinicalExpenses	1365000	usd
CY2021Q4	krys	Accrued Preclinical And Clinical Expenses AccruedPreclinicalAndClinicalExpenses	1602000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3397000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2011000	usd
CY2022Q4	krys	Accrued Payroll And Benefits AccruedPayrollAndBenefits	6781000	usd
CY2021Q4	krys	Accrued Payroll And Benefits AccruedPayrollAndBenefits	2882000	usd
CY2022Q4	krys	Accrued Construction In Progress And Laboratory Equipment AccruedConstructionInProgressAndLaboratoryEquipment	11452000	usd
CY2021Q4	krys	Accrued Construction In Progress And Laboratory Equipment AccruedConstructionInProgressAndLaboratoryEquipment	9606000	usd
CY2022Q4	krys	Accrued Financing Fees Current AccruedFinancingFeesCurrent	0	usd
CY2021Q4	krys	Accrued Financing Fees Current AccruedFinancingFeesCurrent	26000	usd
CY2022Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	43000	usd
CY2021Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	83000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	267000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	87000	usd
CY2022Q4	krys	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	23305000	usd
CY2021Q4	krys	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	16297000	usd
CY2022	krys	Purchase Price Of Potential Building Purchase PurchasePriceOfPotentialBuildingPurchase	16300000	usd
CY2021Q3	krys	Loss Contingency Guaranteed Maximum Price To Be Paid LossContingencyGuaranteedMaximumPriceToBePaid	85500000	usd
CY2022	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	1100000	usd
CY2021	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	1600000	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	560000	usd
CY2020Q4	krys	Purchase Price Of Potential Building Purchase PurchasePriceOfPotentialBuildingPurchase	9400000	usd
CY2020Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	10000000	usd
CY2020Q4	krys	Payment To Escrow For Reducing Lease Rentals PaymentToEscrowForReducingLeaseRentals	2400000	usd
CY2020Q4	krys	Purchase Price Of Potential Building Purchase PurchasePriceOfPotentialBuildingPurchase	9400000	usd
CY2020Q4	us-gaap	Escrow Deposit EscrowDeposit	1500000	usd
CY2022	krys	Lessor Operating Lease Liability Annual Lease Payments LessorOperatingLeaseLiabilityAnnualLeasePayments	82000	usd
CY2022	krys	Cumulative Escalation Clause Percent CumulativeEscalationClausePercent	0.10
CY2022	krys	Cumulative Escalation Clause Term CumulativeEscalationClauseTerm	P5Y
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1648000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1539000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1277000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1277000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1300000	usd
CY2022Q4	krys	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	10762000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	17803000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8870000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8933000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8042000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7228000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1561000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1041000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7372000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6983000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8933000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8024000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y6M
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P14Y4M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.094
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.095
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1532000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1275000	usd
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	767000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	226000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	160000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1422450	shares
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	57000	usd
CY2022	us-gaap	Lease Cost LeaseCost	1758000	usd
CY2021	us-gaap	Lease Cost LeaseCost	1435000	usd
CY2020	us-gaap	Lease Cost LeaseCost	824000	usd
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	227000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	198000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	853614	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	40.31
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	16804000	usd
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	66.88
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	54260	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	38.12
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	175750	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	61.35
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2875	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	75.82
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2043179	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	57.00
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	31331000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2130500	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	64.14
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	138855	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	50.47
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	438892	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	59.22
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	13751	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	78.80
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3582181	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	61.50
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	64880000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	666886	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	49.20
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y6M
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	20055000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31448000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13669000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3272000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	551000	usd
CY2021	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	284000	usd
CY2020	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	34000	usd
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6752000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-29395000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-14578000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	39781000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	20689000	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	11112000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-10438000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-5436000	usd
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2632000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	1736000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	1295000	usd
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	887000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	2182000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	675000	usd
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-216000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-394000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-55000	usd
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-625000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	52569000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	33170000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7445000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3906000	usd
CY2022Q4	krys	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	2572000	usd
CY2021Q4	krys	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	2344000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	679000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2206000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	817000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	14124000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	884000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	6708000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3607000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Availablefor Sale Securities Gross DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross	192000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Availablefor Sale Securities Gross DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross	49000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	85816000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	45456000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	82513000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42732000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3303000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2724000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	137000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	usd
CY2022Q4	krys	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	2312000	usd
CY2021Q4	krys	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	2111000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	854000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	613000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3303000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2724000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022	krys	Ownership Interest Rate Change Over Period OwnershipInterestRateChangeOverPeriod	P3Y

Files In Submission

Name	View Source	Status
krys-20221231_cal.xml	Edgar Link	unprocessable
0001711279-23-000008-index-headers.html	Edgar Link	pending
0001711279-23-000008-index.html	Edgar Link	pending
0001711279-23-000008.txt	Edgar Link	pending
0001711279-23-000008-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
krys-20221231.htm	Edgar Link	pending
krys-20221231.xsd	Edgar Link	pending
krys-20221231ex1023xformof.htm	Edgar Link	pending
krys-20221231ex211xlistofs.htm	Edgar Link	pending
krys-20221231ex231xkpmgcon.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
krys-20221231ex232xmhmcons.htm	Edgar Link	pending
krys-20221231ex311.htm	Edgar Link	pending
krys-20221231ex312.htm	Edgar Link	pending
krys-20221231ex321.htm	Edgar Link	pending
krys-20221231ex43xdescript.htm	Edgar Link	pending
krys-20221231_g1.jpg	Edgar Link	pending
krys-20221231_g2.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
krys-20221231_lab.xml	Edgar Link	unprocessable
krys-20221231_pre.xml	Edgar Link	unprocessable
krys-20221231_htm.xml	Edgar Link	completed
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
krys-20221231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KRYS
Krystal Biotech, Inc. Stock $krys

2023 Q1 Form 10-K Financial Statement

#000171127923000008 Filed on February 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KRYS Krystal Biotech, Inc. Stock $krys

2023 Q1 Form 10-K Financial Statement

#000171127923000008 Filed on February 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KRYS
Krystal Biotech, Inc. Stock $krys